StockData

Prelude Therapeutics vs Tango Therapeutics

PRLD and TNGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How PRLD and TNGX compare

Tango Therapeutics is the larger company, worth 14 times as much as Prelude Therapeutics ($3.7B against $265M).

Prelude Therapeutics grew revenue faster over the last twelve months (220% versus 121% for Tango Therapeutics).

Tango Therapeutics keeps more of each dollar of sales as profit, with a net margin of −230% compared with −270% at Prelude Therapeutics.

Tango Therapeutics scores higher on the StockData Score (10 against 8 for Prelude Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricPRLDTNGX
Size and price
Market cap$265M$3.7B
Share price$3.32$22.11
Change, 1 year118%171%
Change, 5 years−76.3%114%
Beta (5Y)1.441.67
Employees79137
StockData Score
Total score810 (better)
Valuation score1 (better)0
Growth score12 (better)
Performance score12 (better)
Health score56 (better)
Dividend score00
Valuation
P/S11.8× (better)69.3×
P/B2.0× (better)3.6×
FCF yield−12.6%−3.9% (better)
Fair value$2.14$9.71
Margin of safety−55.2% (better)−128%
Growth
Revenue growth (TTM)220% (better)121%
Revenue growth, 5Y average–52.1%
Profitability
Operating margin−301%−253% (better)
Net margin−270%−230% (better)
FCF margin−148% (better)−268%
Return on equity−57.7%−21.3% (better)
Financial health
Debt / equity0.000.00
Current ratio4.0750.82 (better)
Altman Z-score−2.6945.17 (better)
Piotroski F-score34 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions62.2%127%
Held by insiders40.5%11.7%
Insider net buying, 12 months$25.0M (better)−$8.1M
Short interest, % of float8.8%32.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.